Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,124 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07201012Recruiting
Finding skin tumors in Lynch syndrome patients
This study looks for Muir-Torre syndrome, a condition that causes certain skin tumors, in people who already have Lynch syndrome. It may help doctors understand how common this skin condition is in Lynch syndrome patients.
Nîmes, GardAges Any age - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Sarasota, FloridaAges 18 years+ - NCT07188103RecruitingPhase 2
Ivonescimab and short radiation for advanced esophageal cancer
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
Hefei, AnhuiAges 18–80 - NCT07187778RecruitingPhase 2
Kidney cancer treatment before surgery
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Houston, TexasAges 18 years+ - NCT07186530Enrolling by invitation
HPV self-collection for cervical cancer screening
This trial tests a new way for women to screen for cervical cancer by collecting their own sample for HPV testing at home or in a clinic. It aims to make screening easier for those who are overdue and may be anxious about a pelvic exam.
Rochester, MinnesotaAges 30–63 - NCT07186010Recruiting
Immune therapy biomarkers in advanced liver cancer
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
Seoul, Song-paAges 19 years+ - NCT07190755Recruiting
Symptom tracking with a smartphone app for head and neck cancer
This trial uses a smartphone app to track your symptoms during radiation treatment for head and neck cancer. It aims to help your care team catch problems early and improve your quality of life.
RouenAges 18–75 - NCT07187869RecruitingPhase 1
Cabozantinib plus nivolumab for kidney cancer with bone spread
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Houston, TexasAges 18 years+ - NCT05201404RecruitingPhase 3
Namodenoson for advanced liver cancer with moderate cirrhosis
This Phase 3 trial studies whether namodenoson can slow or control advanced hepatocellular carcinoma (liver cancer) in people whose cirrhosis is in a specific middle range. It may help if standard treatments have not worked or the cancer has spread and is not expected to be cured.
Dallas, TexasAges 18 years+ - NCT06102863RecruitingPhase 2
Progesterone and statins for young women with early endometrial cancer or atypical hyperplasia
This trial tests whether adding a statin to progesterone therapy helps young women with early endometrial cancer or atypical endometrial hyperplasia who want to preserve their fertility. It aims to find a better treatment option for those who may not respond well to progesterone alone.
Beijing, Beijing MunicipalityAges 17–45 - NCT06587802RecruitingPhase 2
PD-1 antibody and radiation for advanced adrenal cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT07182240Recruiting
Study of a new imaging method for skin cancer surgery
This study is testing a new imaging technology that helps surgeons see if all the cancer cells have been removed during Mohs surgery for basal cell carcinoma. It may help improve accuracy and reduce the need for additional surgeries.
Buffalo, New YorkAges 18 years+ - NCT07175480RecruitingPhase 2
Stopping treatment for kidney cancer based on PET/CT results
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
Nanjing, JiangsuAges 18 years+ - NCT07178301RecruitingPhase 2
Lower radiation dose for HPV-related throat cancer
This trial tests whether a lower dose of radiation to the neck is safe and effective for people with HPV-related oropharyngeal cancer. It may reduce side effects while still treating the cancer.
Chicago, IllinoisAges 18 years+ - NCT07179900RecruitingPhase 2
Radiation plus two drugs for liver cancer that can't be removed
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
Shijiazhuang, HebeiAges 18 years+ - NCT07177443RecruitingPhase 3
Immunotherapy with chemo and radiation for nasopharyngeal cancer
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
Wuhan, HubeiAges 18–65 - NCT07179770RecruitingPhase 1
Belzutifan and imaging in advanced kidney cancer
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
New York, New YorkAges 18 years+ - NCT07178587Recruiting
New PET scan for liver and neuroendocrine tumors
This trial tests a new PET imaging method that uses two different tracers to find and stage liver cancer (HCC) or neuroendocrine tumors (GEP-NET) more accurately. It may help doctors decide on the best treatment for you.
BrestAges 18 years+ - NCT07178847Recruiting
Cancer DNA after chemoradiation for head and neck cancer
This study looks for cancer DNA left in the body after standard chemoradiation for advanced head and neck squamous cell cancer. It aims to understand if this residual DNA means the disease is more likely to come back.
Aurillac, CANTALAges 18–80 - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07175441RecruitingPhase 2
Testing a new drug combo for advanced liver cancer
This trial tests a new drug called RBS2418 added to two immunotherapy medicines (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination helps patients who are starting their first treatment for this stage of liver cancer.
Baltimore, MarylandAges 18 years+ - NCT07170345Recruiting
AI to detect hidden spread in liver cancer from scans
This trial uses a computer program to help doctors find signs of microscopic tumor spread in blood vessels (microvascular invasion) from liver cancer images. It aims to improve treatment planning for patients who are having surgery.
Fuzhou, FujianAges 18–18 - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,124 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.